

RECEIVED
CENTRAL FAX CENTER

JAN 06 2009

IN THE CLAIMS

Claims 1-60 were initially filed with the application. Claims 13-36, 51 and 58 have been canceled without prejudice or disclaimer of the subject matter therein. Claims 1-12, 37-50, 52-57 and 59-60 are currently pending in this application and are subject to rejection. Herein, Applicant presents amendments to claims 1-3, 6, 8-10, 12, 37-38, 40, 43, 45-46, 49-50, 52-57 and 59-60 without prejudice or disclaimer of the subject matter thereof.

We Claim:

1. (Currently Amended) A method of inhibiting bacterial colonization of mucous epithelium in a biological system comprising;

administering to said biological system a bacterial colonising inhibitor comprising an effective amount of a mucolytic agent and a milk product selected from the group consisting of colostrum, hyperimmune milk, a component of colostrum and a component of hyperimmune milk capable of inhibiting bacterial colonization in combination with the mucolytic agent; composition comprising a mucolytic agent and an antibacterial component isolated from hyperimmune colostrum or hyperimmune milk.
2. (Currently Amended) The method of claim 1, wherein said ~~inhibition of bacterial colonization occurs~~ mucous epithelium is in the gastrointestinal tract.
3. (Currently Amended) The method of claim 1, wherein said bacterial are ~~colonization is~~ by a Helicobacter species.

4. (Original) The method of claim 3, wherein said *Helicobacter* species is *Helicobacter pylori*.
5. (Original) The method of claim 1, wherein said mucolytic agent is N-acetyl cysteine.
6. (Currently Amended) The method of claim 1, wherein said antibacterial component of hyperimmune colostrum or hyperimmune milk is lactoferrin.
7. (Original) The method of claim 6, wherein said lactoferrin is hydrolyzed.
8. (Currently Amended) The method of claim 1, wherein said ~~milk product originates from a bovine~~, hyperimmune colostrum or hyperimmune milk is of bovine origin.
9. (Currently Amended) The method of claim 1, wherein a said antibacterial component of hyperimmune colostrum or hyperimmune milk is an antibody ~~milk product includes antibodies~~ selected from the group consisting of specific antibodies and cross-reactive antibodies to the bacteria, ~~colonising the mucous epithelium~~.
10. (Currently Amended) The method of claim 1, ~~wherein said method further includes~~ comprising administration of an antibiotic.
11. (Original) The method of claim 10, wherein said antibiotic is amoxicillin.
12. (Currently Amended) The method of claim 1, wherein said biological system is selected from the group consisting of a human or and non-human animal.
- 13-36. (Canceled)

37. (Currently Amended) A method for treating a disease or condition associated with bacterial infection of mucous epithelium in a subject comprising;

administering to said subject an effective amount of a ~~mucolytic agent and a milk product selected from the group consisting of colostrum, hyperimmune milk, a component of colostrum and a component of hyperimmune milk capable of~~ combination comprising a mucolytic agent and an antibacterial agent isolated from hyperimmune colostrum or hyperimmune milk which ~~treating~~s the disease or condition associated with bacterial infection of mucous epithelium, ~~in combination with the mucolytic agent.~~

38. (Currently Amended) The method of claim 37, wherein ~~said disease or condition is associated with bacterial infection of~~ the mucous epithelium is in the gastrointestinal tract.

39. (Original) The method of claim 37, wherein said disease or condition is selected from the group consisting of gastric inflammation, an ulcer of the stomach, an ulcer of the duodenum, non-ulcer dyspepsia, and a gastric condition associated with leukocyte infiltration.

40. (Currently Amended) The method of claim 37, wherein said bacterial ~~colonization is by a~~ are *Helicobacter* species.

41. (Original) The method of claim 40, wherein said *Helicobacter* species is *Helicobacter pylori*.

42. (Original) The method of claim 37, wherein said mucolytic agent is N-acetyl cysteine.

43. (Currently Amended) The method of claim 37, wherein said antibacterial component of hyperimmune colostrum or hyperimmune milk is lactoferrin.

44. (Original) The method of claim 43, wherein said lactoferrin is hydrolyzed.

45. (Currently Amended) The method of claim 37, wherein said ~~milk product originates from a bovine~~ hyperimmune colostrum or hyperimmune milk is of bovine origin.

46. (Currently Amended) The method of claim 37, wherein a said ~~milk product includes~~ antibacterial component of hyperimmune colostrum or hyperimmune milk is an antibody selected from the group consisting of specific antibodies and cross-reactive antibodies to the bacteria, ~~infecting the mucous epithelium.~~

47. (Original) The method of claim 37, wherein said method further includes administration of an antibiotic.

48. (Original) The method of claim 47, wherein said antibiotic is amoxicillin.

49. (Currently Amended) The method of claim 37, wherein said biological system is selected from the group consisting of a human or and a non-human animal.

50. (Currently Amended) A composition comprising;

N-acetyl cysteine and an antibacterial component isolated from hyperimmune colostrum or hyperimmune milk.

~~a mucolytic agent and a milk product selected from the group consisting of colostrum, hyperimmune milk, a component of colostrum and a component of hyperimmune milk~~

51. (Canceled)

52. (Currently Amended) The method composition of claim 50, wherein said ~~milk product originates from a bovine~~ colostrum or milk is of bovine origin.

53. (Currently Amended) The ~~method~~ composition of claim 50, wherein said antibacterial component of hyperimmune colostrum or hyperimmune milk is lactoferrin.

54. (Currently Amended) The ~~method~~ composition of claim 53, wherein said lactoferrin is hydrolyzed.

55. (Currently Amended) The ~~method~~ composition of claim 50, wherein said ~~milk product~~ includes antibacterial component of hyperimmune colostrum or hyperimmune milk is an antibody selected from the group consisting of specific antibodies and cross-reactive antibodies to the bacteria, ~~colonising the mucous epithelium.~~

56. (Currently Amended) The ~~method~~ composition of claim 50, ~~wherein said method~~ further ~~includes administration of~~ comprising an antibiotic.

57. (Currently Amended) The ~~method~~ composition of claim 56, wherein said antibiotic is amoxicillin.

58. (Canceled)

59. (Currently Amended) The ~~method~~ composition of claim 50, wherein ~~said bacteria is the~~ antibacterial component inhibits a *Helicobacter* species.

60. (Currently Amended) The composition of claim 59, wherein said *Helicobacter* species is *Helicobacter pylori*.